Immatics Biotechnologies Gets $9.9 Million In Initial Venture Round

Immatics Biotechnologies, a start-up that is developing peptide-based therapeutics for cancer immunotherapy, said it has raised EUR 7.75 million ($9.9 million) in its initial round of venture funding.